# Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients

> **NCT00929019** · PHASE1,PHASE2 · TERMINATED · sponsor: **Radboud University Medical Center** · enrollment: 23 (actual)

## Conditions studied

- Uveal Melanoma

## Interventions

- **BIOLOGICAL:** autologous dendritic cells electroporated with mRNA

## Key facts

- **NCT ID:** NCT00929019
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-06
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2018-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00929019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00929019, "Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00929019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*